Treatment Patterns and Clinical Outcomes in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer After Progression...

Area of Science:

• Oncology
• Medical Research

Background:

• Optimal second-line treatment for advanced EGFR-mutated non-small-cell lung cancer (NSCLC) after osimertinib progression remains unknown.
• Current practice patterns for subsequent therapies are diverse.

Purpose of the Study:

• To assess treatment patterns in patients with EGFR-mutated NSCLC post-first-line osimertinib progression.
• To evaluate the association between different second-line therapies and patient survival outcomes.

Main Methods:

• Retrospective cohort study utilizing a deidentified, nationwide electronic health record database.
• Analysis included 538 patients with available second-line treatment data after first-line osimertinib.

Main Results:

• Second-line regimens varied, commonly including chemotherapy (65%), immune checkpoint inhibitors (37%), and EGFR tyrosine kinase inhibitors (44%).
• Continuation of osimertinib with chemotherapy in 333 patients (performance status 0-2) showed superior progression-free survival (10.1 vs. 5.9 months) and overall survival (17.0 vs. 12.8 months) versus chemotherapy alone.
• This benefit was most significant in patients with EGFR exon 19 deletions.

Conclusions:

• A wide array of second-line treatments are employed following osimertinib progression in EGFR-mutated NSCLC.
• Continuing osimertinib in combination with chemotherapy demonstrates improved progression-free and overall survival.